Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Genmab
Tango Therapeutics, Inc.
Sotio Biotech Inc.
Royal Marsden NHS Foundation Trust
Takeda
Novartis
VM Oncology, LLC
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Incyte Corporation
Merck Sharp & Dohme LLC
Turnstone Biologics, Corp.
Canadian Cancer Trials Group
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
National Institutes of Health Clinical Center (CC)
Incyte Corporation
NHS Greater Glasgow and Clyde
Case Comprehensive Cancer Center